India-based drugmaker Strides Pharma (NSE: STAR) has received a warning from the US Food and Drug Administration, after being caught shredding documents related to quality control.
US FDA inspectors said they found records in the process of being destroyed, and that discarded documents were also retrieved from a garbage can.
The letter, which warns of Good Manufacturing Practice (GMP) violations at its Puducherry facility, also alleges the firm made inadequate investigations regarding out-of-specification (OOS) test results.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze